Lymphoproliferative disorders in pediatric liver allograft recipients: A review of 212 cases

Hematology/ Oncology and Stem Cell Therapy

Volumn 5, Issue 2, 2012, Pages 84-90

  Khedmat, Hossein ^a   Taheri, Saeed ^b  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Dr Taheri Medical Research Group   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GRAFT RECIPIENT; HEALTH DISPARITY; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORTALITY; OUTCOME ASSESSMENT; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PROGNOSIS; REMISSION; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME;

EID: 84866939701     PISSN: 16583876     EISSN: None     Source Type: Journal    
DOI: 10.5144/1658-3876.2012.84     Document Type: Article

References (59)

1. Khedmat H, Taheri S. Early versus late outset of lymphoproliferative disorders post-heart and lung transplantation: The PTLD.Int Survey. Hematol Oncol Stem Cell Ther. 2011;4(1):10-6.
2. Khedmat H, Taheri S. Post-Transplantation Lymphoproliferative disorders localizing in the adenotonsillar region: Report from the PTLD.Int survey. Ann Transplant. 2011 Mar 23;16(1):109-16.
3. Izadi M, Taheri S. Features, predictors and prognosis of lymphoproliferative disorders post-liver transplantation regarding disease presentation time: Report from the PTLD.Int. survey. Ann Transplant. 2011 Mar 23;16(1):39-47.
4. Khedmat H, Taheri S. Characteristics and prognosis of post-transplant lymphoproliferative disorders within renal allograft: Report from the PTLD. Int. Survey. Ann Transplant. 2010 Sep 28;15(3):80-6.
5. Izadi M, Fazel M, Saadat SH, Taheri S. Hepatic involvement by lymphoproliferative disorders post liver transplantation: PTLD.Int. Survey. Hepatol Int. 2011 Sep;5(3):759-66.
6. Izadi M, Taheri S. Significance of in situ hybridization results for EBV-encoded RNA in posttransplantation lymphoproliferative disorder setting: Report from the PTLD.Int Survey. Ann Transplant. 2010 Dec 22;15(4):102-9.
7. Khedmat H, Alavian SM, Taheri S. Significance of Epstein-Barr virus infection in the outcome of renal transplant patients with lymphoproliferative disorders. Ann Transplant, 2010; 15(2): 40-44.
8. Magrath IT, Rowe M, Filipovich AH, et al. Advances in understanding of EBV associated lymphoproliferative disorders. In Ablashi DV, ed. EBV and human disease. Clifton, NJ: Human Press, 1991; 243.
9. Smets F, Sokal EM. Epstein-Barr virus-related lymphoproliferation in children after liver transplant: role of immunity, diagnosis, and management. Pediatr Transplant 2002; 6: 280-287.
10. Penn I. De novo malignancies in pediatric organ transplant recipients. Pediatr Transplant 1998; 2: 56-63.
11. Cacciarelli TV, Green M, Jaffe R, Mazariegos GV, Jain A, Fung JJ, Reyes J. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation. 1998 Oct 27;66(8):1047-52.
12. Younes BS, McDiarmid SV, Martin MG et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 2000; 70: 94-99.
13. Berg LC, Copenhaver CM, Morrison VA, Gruber SA, Dunn DL, Gajl-Peczalska K, Strickler JG. B-cell lymphoproliferative disorders in solid-organ transplant patients: detection of Epstein-Barr virus by in situ hybridization. Hum Pathol. 1992 Feb;23(2):159-63.
14. Kogan-Liberman D, Burroughs M, Emre S, Moscona A, Shneider BL. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience. J Ped Gastroenterol 2001;33:445-449.
15. Arbus GS, Grisaru S, Segal O, Dosch M, Pop M, Lala P, Nutikka A, Lingwood CA. Verotoxin targets lymphoma infiltrates of patients with post-transplant lymphoproliferative disease. Leuk Res. 2000 Oct;24(10):857-64.
16. Roque J, Rios G, Humeres R, Volpi C, Herrera JM, Schultz M, Rios H, Rius M, Salgado C, Hepp J. Early posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Transplant Proc. 2006 Apr;38(3):930-1.
17. Huang RY, Shapiro NL. Adenotonsillar enlargement in pediatric patients following solid organ transplantation. Arch Otolaryngol Head Neck Surg. 2000 Feb;126(2):159-64.
18. Wu JF, Ho MC, Ni YH, Chen HL, Lu CY, Hsu HY, Lee PH, Chang MH. Timing of Epstein-Barr virus acquisition and the course of posttransplantation lymphoproliferative disorder in children. Transplantation. 2009 Mar 15;87(5):758-62.
19. Uribe M, Hunter B, Alba A, Calabrán L, Flores L, Soto P, Herzog C. Posttransplant lymphoproliferative disorder in pediatric liver transplantation. Transplant Proc. 2009 Jul-Aug;41(6):2679-81.
20. Porter CC, Liang X, Gralla J, McGavran L, Albano EA. BCL6 expression correlates with monomorphic histology in children with posttransplantation lymphoproliferative disease. J Pediatr Hematol Oncol. 2008 Sep;30(9):684-8.
21. Gheorghe G, Albano EA, Porter CC, McGavran L, Wei Q, Meltesen L, Danielson SM, Liang X. Posttransplant Hodgkin lymphoma preceded by polymorphic posttransplant lymphoproliferative disorder: report of a pediatric case and review of the literature. J Pediatr Hematol Oncol. 2007 Feb;29(2):112-6.
22. De Diego JI, Prim MP, Hardisson D, Verdaguer JM, Jara P. Post-transplant lymphoproliferative disease in tonsils of children with liver transplantation. Int J Pediatr Otorhinolaryngol. 2001 Apr 27;58(2):113-8.
23. Collins MH, Montone KT, Leahey AM, et al. Post-transplant lymphoproliferative disease in children. Pediatr Transplant. 2001;5:250-257.
24. Kerkar N, Morotti RA, Madan RP, Shneider B, Herold BC, Dugan C, Miloh T, Karabicak I, Strauchen JA, Emre S. The changing face of posttransplant lymphoproliferative disease in the era of molecular EBV monitoring. Pediatr Transplant. 2010 Jun;14(4):504-11. Epub 2010 Jan 7.
25. Djokic M, Le Beau MM, Swinnen LJ, Smith SM, Rubin CM, Anastasi J, Carlson KM. Posttransplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities. Genes Chromosomes Cancer. 2006 Mar;45(3):313-8.
26. Allen UD, Farkas G, Hebert D, et al. Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: a casecontrol study. Pediatr Transplant 2005;9:450-5.
27. Praghakaran K, Wise B, Chen A et al. Rational management of posttransplant lymphoproliferative disorder in pediatric recipients. J Pediatr Surg 1999: 34: 112-116.
28. Norin S, Kimby E, Ericzon BG, Christensson B, Sander B, Söderdahl G, Hägglund H. Posttransplant lymphoma--a single-center experience of 500 liver transplantations. Med Oncol. 2004;21(3):273-84.
29. Jens Martin Rohrbach. EBV-induced polymorphic lymphoproliferative disorder of the iris after heart transplantation. Graefes Arch Clin Exp Ophthalmol. 2004 Jan;242(1):44-50. Epub 2003 Dec 9.
30. Sharon. Increased Levels of Circulating Epstein-Barr Virus (EBV)-Infected Lymphocytes and Decreased EBV Nuclear Antigen Antibody Responses Are Associated With the Development of Posttransplant Lymphoproliferative Disease in Solid-Organ Transplant Recipients
31. Castellano-Sanchez AA, Li S, Qian J, Lagoo A, Weir E, Brat DJ. Primary central nervous system post-transplant lymphoproliferative disorders. Am J Clin Pathol. 2004;121: 246-253.
32. Wilde GE, Moore DJ, Bellah RD. Posttransplantation lymphoproliferative disorder in pediatric recipients of solid organ transplants: timing and location of disease. AJR Am J Roentgenol. 2005 Nov;185(5):1335-41.
33. Dotti G, Fiocchi R, Motta T et al. Lymphoma occurring late after solid organ transplantation: influence of treatment on the clinical outcome. Transplantation, 2002: 74: 1095.
34. Smets F, Vajro P, Cornu G, Reding R, Otte JB, Sokal E. transplant lymphoproliferative disease after liver transplantation. Transplantation 2000;69:982-5.
35. Carpentier L, Tapiero B, Alvarez F, et al. EpsteinBarr virus (EBV) early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease. J Infect Dis 2003; 188: 1853.
36. Ifthikharuddin JJ, Mieles LA, Rosenblatt JD, Ryan CK, Sahasrabudhe DM. CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab. Am J Hematol. 2000 Oct;65(2):171-3.
37. Weissmann DJ, Ferry JA, Harris NL, Louis DN, Delmonico F, Spiro I. Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol 1995; 103:748-55.
38. Benkerrou M, Durandy A, Fischer A. Therapy for transplant-related lymphoproliferative disease. Hematol Oncol Clin North Am 1993; 7:467-475.
39. Boscà-Robledo A, Pous-Serrano S, GarcíaMayor RL, Trilles-Olaso LM. Acute abdomen as the first manifestation of a post-transplant lymphoproliferative disorder. Int J Colorectal Dis. 2011 Aug;26(8):1081-2.
40. Medlicott SA, Devlin S, Helmersen DS, Yilmaz A, Mansoor A. Early post-transplant smooth muscle neoplasia of the colon presenting as diminutive polyps: a case complicating post-transplant lymphoproliferative disorder. Int J Surg Pathol. 2006 Apr;14(2):155-61.
41. Chen W, Huang Q, Zuppan CW, Rowsell EH, Cao JD, Weiss LM, Wang J. Complete absence of KSHV/HHV-8 in posttransplant lymphoproliferative disorders: an immunohistochemical and molecular study of 52 cases. Am J Clin Pathol. 2009 May;131(5):632-9.
42. Orjuela M, Gross TG, Cheung YK, Alobeid B, Morris E, Cairo MS. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3945S-52S.
43. McCormack L, Hany TI, Hübner M, Petrowsky H, Mullhaupt B, Knuth A, Stenner F, Clavien PA. How useful is PET/CT imaging in the management of post-transplant lymphoproliferative disease after liver transplantation? Am J Transplant. 2006 Jul;6(7):1731-6.
44. Morrison VA, Dunn DL, Manivel JC, Gajl Peczalska KJ, Peterson BA. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994;97:14-24.
45. Gallego S, Llort A, Gros L, Sanchez de Toledo J Jr, Bueno J, Moreno A, Nieto J, Sanchez de Toledo J. Post-transplant lymphoproliferative disorders in children: the role of chemotherapy in the era of rituximab. Pediatr Transplant. 2010 Feb;14(1):61-6.
46. Timuragaoglu A, Ugur-Bilgin A, Colak D, Tuncer M, Gölbasi I, Hazar V, Kiliçarsłan B, Undar L, Demirbas A. Posttransplant lymphoproliferative disorders in transplant recipients. Transplant Proc. 2006 Mar;38(2):641-5.
47. Vakiani E, Basso K, Klein U, Mansukhani MM, Narayan G, Smith PM, et al. Genetic and phenotypic analysis of B-cell posttransplant lymphoproliferative disorders provides insights into disease biology. Hematol Oncol 2008;26:199-211.
48. Baldanti F, Grossi P, Furione M, Simoncini L, Sarasini A, Comoli P, Maccario R, Fiocchi R, Gerna G. High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiol. 2000 Feb;38(2):613-9.
49. Comoli P, Labirio M, Basso S, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002: 99: 2592-2598.
50. Poirel HA, Bernheim A, Schneider A. Characteristic Pattern of Chromosomal Imbalances in Posttransplantation Lymphoproliferative Disorders: Correlation with Histopathological Subcategories and EBV Status. Transplantation 2005; 80(2):176-184.
51. Kenagy DN, Schlesinger Y, Weck K, et al. Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation 1995;60:547-54.
52. Mathur RV, Kudesia G, Suvarna K, McKane W. Fulminant post-transplant lymphoproliferative disorder presenting with lactic acidosis and acute liver failure. Nephrol Dial Transplant. 2004 Jul;19(7):1918-20.
53. Doria C, Marino IR, Scott VL, et al. Posttransplant lymphoproliferative disorders presenting at sites of previous surgical intervention. Transplantation 2003; 75: 1066.
54. Johnson LR, Nalesnik MA, Swerdlow SH. Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study. Am J Surg Pathol. 2006 Dec;30(12):1604-12.
55. Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE; North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation. 2001 Apr 27;71(8):1065-8.
56. Guthery SL, Heubi JE, Bucuvalas JC, Gross TG, Ryckman FC, Alonso MH, Balistreri WF, Hornung RW. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation. 2003 Apr 15;75(7):987-93.
57. Smith JM, Corey L, Healey PJ, Davis CL, McDonald RA. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients. Transplantation. 2007 Jun 15;83(11):1423-8.
58. Shapiro R, Nalesnik M, McCauley J, Fedorek S, Jordan ML, Scantlebury VP, Jain A, Vivas C, Ellis D, Lombardozzi-Lane S, Randhawa P, Johnston J, Hakala TR, Simmons RL, Fung JJ, Starzl TE. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation. 1999 Dec 27;68(12):1851-4.
59. Hayashi RJ, Kraus MD, Patel AL, Canter C, Cohen AH, Hmiel P, Howard T, Huddleston C, Lowell JA, Mallory G Jr, Mendeloff E, Molleston J, Sweet S, DeBaun MR. Posttransplant lymphoproliferative disease in children: correlation of histology to clinical behavior. J Pediatr Hematol Oncol. 2001 Jan;23(1):14-8.